Linked Life Data

17048031

Source:http://linkedlifedata.com/resource/pubmed/id/17048031

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-12-12
pubmed:abstractText
Female sexual dysfunction (FSD) is considered a common medical problem estimated to affect millions of women in the westernized countries. FSD has been classified into four different categories including sexual arousal disorder (FSAD), sexual desire disorder (HSDD), orgasmic disorder and sexual pain disorder. The focus of this article is the potential role of pharmacological compounds currently under development, in the treatment of sexual arousal and orgasmic disorders in order to enhance the sexual response in adult females. While a number of potential therapeutic options are available to date, not one of the pharmacological treatment regimens has been yet considered the Gold standard in the management of symptoms of FSD. This article reviews the rationale and potential benefits of using distinct drug formulations in the treatment of FSD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0724-4983
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
630-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Potential future options in the pharmacotherapy of female sexual dysfunction.
pubmed:affiliation
Department of Urology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. sue_de_99@yahoo.de
pubmed:publicationType
Journal Article, Review